News Releases

Date	Title
10/10/2024	Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids	PDF Version
09/25/2024	Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")	PDF Version
09/03/2024	Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer	PDF Version
08/06/2024	Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance	PDF Version
07/30/2024	Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024	PDF Version
07/15/2024	Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System	PDF Version
07/02/2024	Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")	PDF Version
05/29/2024	Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")	PDF Version
05/07/2024	Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates	PDF Version
04/24/2024	Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024	PDF Version

Keyword Search